Pictor Biotech Consolidates Biomanufacturing Power

In a strategic move announced on January 22, 2025, Pictor Biotech Inc., operating as SOLARBIOTECH, alongside GPC Bio and Eleszto Genetika, have completed a significant acquisition and strategic unification under a single ownership. This consolidation creates an advanced synthetic biology and biomanufacturing entity, aiming to exploit the potential of precision fermentation. By combining their expertise, the organizations are set to transform synthetic biology innovation, optimizing processes from research and development to commercial production. This merger involves more than 100 professionals, including scientists and biotech executives, underscoring a notable advancement in the domain of biomanufacturing. By unifying these entities, the groups can provide comprehensive support across all biomanufacturing steps, such as microbial strain development, plant engineering, and large-scale operations. Alex Berlin, CEO of SOLARBIOTECH, highlighted that the unification addresses technical impediments in microbial strain engineering and scaling bioprocesses, providing the momentum required for industry growth. Each organizational leader expressed confidence in overcoming current biomanufacturing challenges, leveraging nearly two decades of expertise to efficiently transition products to commercialized production. As part of the unification, Peter Rosholm will focus on investing in sustainable biomanufacturing technologies, reinforcing the new group's capabilities in the burgeoning biotech field. Each entity retains its executive management, with Rosholm exclusively contributing from an ownership perspective. This merger represents a significant step toward enhancing client services and achieving sustained growth in synthetic biology and biomanufacturing.